In our center, odevixibat was effective in patients with PFIC1 and PFIC2 (except in the cases of PFIC2 with BSEP3 subtype mutations), leading to control of symptoms and improvements in sleep, as well as improvements in cholestasis as measured by serum bile acid levels. The gene discussed is ATP8B1; the disease is cholestasis.